Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal study of ...

Resolution of subjective symptoms was achieved in 63% of cases; AST diminished on average by 36%, ALT by 34% and GGT by 46%. Furthermore, the investigators reported a reduction in hepatomegaly ...

Bezuclastinib plus sunitinib showed favorable safety and efficacy in GIST, outperforming sunitinib alone in phase 3 Peak ...

Treatment with bezuclastinib plus Sutent led to safe and efficacious outcomes versus Sutent treatment alone in gastrointestinal stromal tumors.

H.C. Wainwright analyst Robert Burns increased the price target on Bicara Therapeutics Inc (NASDAQ:BCAX) to $45.00 from $42.00, while reiterating a Buy rating on the company's shares. Currently ...

Background: The anti-interleukin (IL) 6 receptor antibody tocilizumab inhibits signalling of IL6, a key cytokine in rheumatoid arthritis (RA) pathogenesis. Objective: To evaluate through the AMBITION ...

Correspondence to Dr Preeti Malik, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; pmalik.ma{at}gmail.com Objective To evaluate association between biomarkers and outcomes in ...

Cell elements compose approximately 45% of the blood; the remaining 55% is the fluid portion ... Sodium, Chloride, Albumin, ALP, ALT, AST, Calcium, Triglycerides, HDL-cholesterol, Total cholesterol, ...

† NASHTest is a combination of age, gender, height, weight serum triglycerides, cholesterol, α2-macroglobulin, apolipoprotein A1, haptoglobin, γ ...

MIDLAND, Texas--(BUSINESS WIRE)--AST SpaceMobile, Inc. (“AST SpaceMobile ... today announced an agreement for long-term access to up to 45 MHz of lower mid-band spectrum in the United ...